News and Announcements
Shivom Extends its Presale Until Friday April 27th, 2018!
- Published April 25, 2018 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Key Takeaways:
- Shivom extends presale to April 27th, 2018, 6 PM GMT
- Shivom receiving overwhelming response for currently presale
- Main crowdsale commences on May 3rd, 2018
Shivom in its bid to help registered users to complete their KYC has extended their Presale for another 2 days! This means you can still sign up for the OmiX Token presale until Friday, April 27th, 2018, 6 PM GMT. The bonus will remain consistently at 3% through the remaining days.
The decision to extend the Presale was taken due to the overwhelming response we have received thus far. Due to the backlog of KYC applications, we are allowing users a few more days to participate, before the main crowdsale commences on May 3rd, 2018. Please note that the crowdsale will not carry any bonuses.
If your KYC application is still incomplete, we recommend you complete it before the main public sale begins.
This also means that the Token Presale is still open for those who haven’t registered yet if you still wish to do so and benefit from the early bird bonuses. Become part of the Shivom’s future-changing project by simply signing up at https://shivom.io/.
Thank you for supporting Shivom in the future of genomic information storage and DNA sequencing. Your participation is vital to our vision and will help empower the next era of global healthcare.
Remember the Presale will end on April 27th, 2018 | 6 PM GMT
About Shivom
Shivom combines blockchain, A.I., DNA sequencing & cryptography to enable secure and personalized medicine. The Shivom platform works on collaboration & integrity, allowing people to own, manage and monetize their data. By creating a web-marketplace, a network of genomic counsellors, and a not-for-profit drug research unit, Shivom will build a global healthcare ecosystem, reaching even low-income countries.
Company Updates
THE TAX CHANGED. NOW THE PRODUCT IS CHANGING TO MATCH.
Changes to the 50% capital gains tax discount are shifting Australian private capital away from growth and into high-yielding wrappers. Fund managers are actively redesigning products across private credit and property to capture the incoming capital rotation
The Algorithm Re-Dosing Cancer Treatment: Inside the University of Melbourne Spin-Out Rewriting a 60-Year-Old Formula
Oncology specialists are still calculating toxic chemotherapy doses using a formula from the era of the Ford Model T, leading to a system where seven out of eight patients are routinely overdosed. University of Melbourne spin-out PredicTx is dismantling this legacy approach, utilizing advanced AI to analyze existing patient CT scans, deliver precision medicine to the bedside, and return a massive 100x financial rerate to hospital networks.
Asset over thematic: Centuria’s Andrew Essey warns against ‘blanket strategies’ as global capital eyes Australia
Relying solely on broad macroeconomic trends is the single biggest mistake property investors make today. Centuria Capital CIO Andrew Essey explains why asset-level “lettability” always trumps the overarching sector thematic, and reveals where global institutional capital is quietly pivoting to capture high-octane returns.
Backed By Leading Investment Groups and Family Offices
